Summary & Overview
HCPCS Q0515: Injection, sermorelin acetate 1 microgram
HCPCS Level II code Q0515 denotes a 1 microgram unit of sermorelin acetate for injection, a synthetic growth hormone–releasing factor used in certain diagnostic and therapeutic contexts. Nationally, drug-specific HCPCS codes like Q0515 matter for accurate billing, inventory tracking, and policy application across payers that cover injectable biologic and peptide products. This code affects clinicians, pharmacies, infusion centers, and payers due to its role in reimbursement and claims adjudication for specialty injectable medications.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical intent of the code, typical sites of service, and which payers are considered. The publication also summarizes expected content areas readers will learn about: national billing benchmarks and coding practice considerations, payer coverage patterns and prior authorization tendencies, and clinical context for sermorelin acetate use. Where specific input data is missing, the summary notes that those details are not available in the input. The focus is national and intended to inform billing staff, revenue-cycle leaders, and policy analysts about the billing identity and operational considerations associated with HCPCS Level II code Q0515.
Billing Code Overview
HCPCS Level II code Q0515 represents Injection, sermorelin acetate, 1 microgram. This code describes the administration of a synthetic growth hormone-releasing factor (sermorelin) in a 1 microgram dosage unit and is used to bill for the drug product itself when supplied for patient administration.
Service Type: Drug administration / Injectable medication
Typical Site of Service: Outpatient clinic, physician office, or ambulatory infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with documented adult growth hormone deficiency (AGHD) presents to an outpatient endocrinology clinic for initiation of diagnostic stimulation and/or ongoing replacement therapy using sermorelin acetate. The patient has fasting blood tests and prior pituitary imaging reviewed; baseline IGF-1 levels are low and prior provocative testing is planned or has been performed. The clinician prescribes Q0515 (injection, sermorelin acetate, 1 microgram) to be administered subcutaneously in the clinic for supervised stimulation testing or taught for home self-administration for daily replacement, depending on the treatment plan. The typical workflow includes: pre-procedure verification of indication and allergies, medication preparation and dose calculation, sterile subcutaneous injection by a registered nurse or trained patient, observation for immediate adverse reactions (30–60 minutes for test administration; brief monitoring for routine replacement dose), documentation of lot number and site, and scheduling of follow-up for laboratory monitoring (IGF-1) and dose adjustments as needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard submission when no special circumstance applies |